Astellas and Ambit Initiate Phase 2b Dose Finding Study of Quizartinib as ... MarketWatch (press release) TOKYO and SAN DIEGO, June 4, 2012 /PRNewswire via COMTEX/ -- Astellas Pharma Inc. (tokyo:4503)(tokyo:Astellas) and Ambit Biosciences Corporation today announced the initiation of a Phase 2b open-label clinical trial of quizartinib as monotherapy in ... Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML |
Saturday, June 9, 2012
Astellas and Ambit Initiate Phase 2b Dose Finding Study of Quizartinib as ... - MarketWatch (press release)
acklinegymejac1362.blogspot.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment